163 related articles for article (PubMed ID: 32205226)
1. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
[TBL] [Abstract][Full Text] [Related]
3. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
[TBL] [Abstract][Full Text] [Related]
5. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
[TBL] [Abstract][Full Text] [Related]
6. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
[TBL] [Abstract][Full Text] [Related]
7. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
[TBL] [Abstract][Full Text] [Related]
10. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
[TBL] [Abstract][Full Text] [Related]
11. A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study.
Yoshida H; Ohki T; Kanezaki M; Teratani T; Sato S; Obi S; Sato T; Akamatsu M; Uchino K; Taniguchi H
BMC Gastroenterol; 2023 Jul; 23(1):250. PubMed ID: 37488476
[TBL] [Abstract][Full Text] [Related]
12. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
Ding Z; Wu H; Zeng Y; Kuang M; Yang W; Meng Z; Chen Y; Hao C; Zou S; Sun H; Liu C; Lin K; Shi G; Wang X; Fu X; Chen R; Chen Y; Liang R; Kano T; Pan H; Yang S; Fan J; Zhou J
Hepatol Int; 2023 Feb; 17(1):180-189. PubMed ID: 36258065
[TBL] [Abstract][Full Text] [Related]
13. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
Shirley M; McCafferty EH; Blair HA
Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.
Nishida Y; Kawaoka T; Imamura M; Namba M; Fujii Y; Uchikawa S; Ohya K; Daijo K; Teraoka Y; Morio K; Fujino H; Nakahara T; Yamauchi M; Hiramatsu A; Tsuge M; Aikata H; Takahashi S; Hayes CN; Fukuhara T; Tsuji K; Arataki K; Nagaoki Y; Aisaka Y; Kamada K; Kodama H; Chayama K
Intern Med; 2021 Mar; 60(6):829-837. PubMed ID: 33087674
[TBL] [Abstract][Full Text] [Related]
15. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
Biolato M; Vitale F; Marrone G; Miele L; Grieco A
Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
[TBL] [Abstract][Full Text] [Related]
16. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease:
Tanaka K; Baba T; Yoshida M; Iguchi M; Sonoyama T; Fukuhara T; Kano T
Curr Med Res Opin; 2022 Feb; 38(2):303-310. PubMed ID: 34904508
[TBL] [Abstract][Full Text] [Related]
17. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.
Brown RS; Imawari M; Izumi N; Osaki Y; Bentley R; Ochiai T; Kano T; Peck-Radosavljevic M
JHEP Rep; 2021 Apr; 3(2):100228. PubMed ID: 33644726
[TBL] [Abstract][Full Text] [Related]
18. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
[TBL] [Abstract][Full Text] [Related]
19. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
